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ORIGINAL ARTICLE
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Abstract
Acute pulmonary embolism (APE) is a common and prognostically signiﬁcant complication of COVID-19 infection.
We investigated the clinical characteristics and chest CT ﬁndings of COVID-19 positive patients complicated with APE.
A retrospective, record-based, case-series study was performed examining 483 patients admitted to King Saud Medical
City during the pandemic, from April 2020 to June 2020. Of these, 92 patients who underwent chest CT scans were
included in the ﬁnal analysis. The incidence of APE, clinical presentations, radiological patterns, and patient outcomes
were assessed and compared against those for patients without PE. The incidence of APE was 22% [95% conﬁdence
interval (95% CI): 19%e39%], detected by chest CT. Men constituted 85.0% of patients, with a mean age of 48.9 ± 16.7
years. For most patients with APE, risk factors for thromboembolism were established but did not differ signiﬁcantly
from those without PE. The mean D-dimer level of 9.1 (range 7.0e10.2) was signiﬁcantly higher among patients diagnosed with APE (OR: 1.021; 95% CI: 1.012e1.028; P ¼ 0.001) compared with that in patients without PE. Moreover, the
mean levels of lactate dehydrogenase (LDH, 628.5; range: 494.0e928.3; OR: 1.002; 95% CI: 1.000e1.003; P ¼ 0.02), Creactive protein (CRP; 158.5; range: 105.3e204.5; OR: 1.025; 95% CI: 1.015e1.035; P ¼ 0.001), and cardiac troponin (3.5;
range; 2.6e3.8; OR: 1.016; 95% CI: 0.971e1.067; P ¼ 0.01) were also signiﬁcantly higher in patients with APE than those in
patients with PE. The chest CT presentations of APE included massive, segmental, and sub-segmental APE. The need for
Intensive Care Unit admission was higher among patients diagnosed with APE, who presented a fatality rate of 10%..
Our study pointed to the incidence and predictors of APE in COVID-19 patients. High levels of D-dimer, CRP, cardiac
troponin, and LDH should alert the clinician to the possibility of APE in COVID-19 patients..
Keywords: Pulmonary embolism, COVID_19, Coagulopathy, Saudi Arabia

1. Introduction

T

he highly communicable disease, known as
coronavirus disease 2019 (COVID-19), associated with the infection of the lower respiratory
tract and caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus, has reached pandemic proportions worldwide since December 2019 [1].

The ﬁrst case of COVID-19 was announced in the
Kingdom of Saudi Arabia on March 2, 2020, with the
bulk of conﬁrmed cases diagnosed in returning
travelers or their immediate contacts. The total
number of conﬁrmed COVID-19 cases reached
313,911 by August 30, 2020, including 3840 associated fatalities [2,3].
COVID-19 presents with a broad range of clinical
manifestations, and the typical onset is associated
with the presentation of non-speciﬁc symptoms,
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such as fever, dry cough, and fatigue. Multiple
systems, including the respiratory, cardiovascular,
neurological, musculoskeletal, and gastrointestinal
systems, may be affected. The condition may rapidly
deteriorate to acute respiratory distress syndrome
(ARDS) in high-risk patients such as elderly and
those with other medical comorbidities, such as
heart, lung, kidney, or liver disorders [4].
COVID-19 infections are frequently correlated
with the activation of the coagulation system,
deﬁned as COVID-19 coagulopathy [5]. Thrombotic
symptoms result in the development of important
sequelae among patients infected with COVID-19,
leading to signiﬁcant morbidity and mortality [6].
Recent studies have indicated that most serious
COVID-19 patients who require Intensive Care Unit
(ICU) admission present with a hypercoagulable
state, which may result in the development of
thromboembolic events [7]. The infection has been
reported to cause endothelial dysfunction and an
inﬂammatory condition, resulting in increased
thrombin production and decreased ﬁbrinolysis [8].
Combined with hypoxia due to severe pneumonia,
these conditions can encourage thrombosis, leading
to the increased viscosity of the blood [9].
Computed tomography (CT) has played a major
role in the diagnosis of COVID-19 since the initial
discovery of the disease and has helped to identify
those patients with severe complications, including
pulmonary embolism (PE) [10,11]. This study aimed
to assess the incidence of acute PE (APE) among
COVID-19 patients and to compare their clinical
presentations, laboratory test results, and outcomes
against those for patients without PE.

2. Patients and methods
A retrospective descriptive, record-based, caseseries, single-center study was performed, which
included adult COVID-19-conﬁrmed patients who
were hospitalized at King Saud Medical City between April 2020 and June 2020. We examined all
483 medical ﬁles for consecutively admitted
COVID-19positive patients. We included all 92 of
these patients who underwent a chest CT scan
during their hospital admission in this study. The
COVID-19 suspicion-to-conﬁrmation process was
driven by the recommendations of the Saudi Centers for Disease Control and Prevention (updated in
June 2020), based on the best available data and
evidence [12]. A conﬁrmed COVID-19 infection was
deﬁned as a positive polymerase chain reaction
(PCR) test. The necessity of a CT scan during hospital admission of COVID-19 positive patients is to
assess the severity of COVID-19 pneumonia and
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rule out PE. The medical criteria used to indicate
chest CT scan included the deterioration of respiration that was not associated with other factors,
acute respiratory distress without improvement,
despite speciﬁc treatment, and increasing D-dimer
levels, in discordance with other inﬂammatory parameters. All CT images were reviewed independently by two experts, and the ﬁnal decisions
reported here were reached by consensus. All demographic data, clinical presentation data
(including clinical symptoms and signs), comorbidities, laboratory ﬁndings, and outcomes were
assessed and compared between COVID-19 patients
with and without PE. Laboratory investigations
included the PCR results for SARS-CoV-2 infection,
complete blood counts, cardiac enzymes [troponin I,
creatinine kinase (CK), CK-MB], D-dimer, C-reactive protein (CRP), prothrombin time, lactate dehydrogenase (LDH), glycated hemoglobin (Hb A1C),
and liver and renal function tests.
This study was approved by the King Saud
Medical City ethics committee. This study was
performed in accordance with the Helsinki declaration and was approved by the Local Ethics and
Research Committee.
2.1. Statistical analysis
Microsoft Excel 2016 and the Social Science Statistical Package (SPSS, version 26.0) for Windows
(SPSS IBM., Chicago, IL) were used to analyze the
results. Continuous variables that were normally
distributed are presented as the mean ± standard
deviation (SD), with a 95% conﬁdence interval (95%
CI), whereas non-normal variables are presented as
the median and interquartile range (IQR). Categorical variables are presented as frequencies and
percentages. A p-value of less than 0.05 was
considered signiﬁcant. The Student's t-test was
performed to compare the means of normally
distributed variables between groups, whereas the
ManneWhitney U test was used to compare the
means of non-normal variables. To compare the
distributions of categorical variables between
groups, the c2 test or Fisher's exact test was used.
Effect modiﬁcations were evaluated by stratiﬁcation,
and statistical interactions were evaluated using
multivariate logistic regression analysis, using main
predictor variables and their product terms in a binary logistic regression analysis.

3. Results
Of 483 COVID-19 positive patients who were
admitted to the hospital during the study period, 92
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Table 1. Demographics and clinical characteristics of the studied groups.

Demographic data, n %:
Age (years) (mean ± SD)
Sex
Female
Male
Nationality
Non-Saudi
Saudi
Delay between admission
and CT diagnosis (Days)
Incidence (Total No. ¼ 92)
History of risk factors, n %:
Diabetes Mellites
Hypertension
Chronic Kidney Disease
Smoker
Obesity (body mass index
over 30)
Cerebro Vascular Accidents
Ischemic Heart Disease
Lung disease.
Clinical presentation, n %:
Fever
Shortness of breath
Cough
Pneumonia
Laboratory investigations, n %:
Hemoglobin, (g/dl)
White Blood Cells, (10^9/L)
Leucopenia, n (%)
Platelets, (10^9/L)
INR
Creatine kinase (U/L)
Lactate Dehydrogenase (U/
L)
Creatine kinase-MB (ng/ml)
Cardiac troponin I (ng/mL)
D-dimer (mg/L)
C-reactive protein (mg/L)
Creatinine (mmol/L)
Urea (mmol/L)
Blood sugar (mmol/L)
Aspartate aminotransferase
(AST) (U/L)
Alanine aminotransferase
(ALT) (U/L)
Total bilirubin (umol/L)
Sodium (mmol/L)
Complications, n %:
ARDS (Acute Respiratory
Distress Syndrome)
Septic shock
RF (Respiratory failure)
ICU admission
Death Rate

APE
N ¼ 20

Non-PE
N ¼ 72

P. value

OR (95%C$I)

P. value

48.9 ± 16.7
3 (15.0%)
17 (85.0%)
17 (85.0%)
3 (15.0%)
4.0 (1.0e12.8)

47.7 ± 14.8
1 (23.6%)
55 (76.4%)
50 (69.4%)
22 (30.6%)
1.0 (1.0e12.0)

0.7
0.4

1.005 (0.973e1.039)
1.752 (0.457e6.706)

0.7
0.4

0.2

0.401 (0.107e1.51)

0.2

0.5

1.032 (0.970e1.098)

0.3

20 (21.7%)

72 (78.3%)

0.001**

22.0 (19.0e39.0)

0.01*

7
4
0
1
0

28 (38.9%)
24 (33.3%)
21 (29.2%)
15 (20.8%)
4 (5.6%)

0.7
0.2
0.01*
0.09
0.3

0.846 (0.301e2.379)
0.5 (0.151e1.66)
0.128 (0.016e1.017)
0.2 (0.025e1.617)
0.673 (0.045e1.031)

0.7
0.3
0.05*
0.1
0.3

3 (15.0%)
2 (10.0%)
2 (10.0%)

7 (9.7%)
4 (5.6%)
5 (6.9%)

0.5
0.5
0.6

1.639 (0.383e7.014)
1.889 (0.320e11.146)
1.489 (0.267e8.318)

0.5
0.5
0.6

16 (80.0%)
16 (80.0%)
15 (75.0%)
6 (30.0%)

56 (77.8%)
59 (81.9%)
62 (86.1%)
8 (11.1%)

0.8
0.8
0.2
0.03*

1.143
0.881
0.484
3.429

(0.335e3.904)
(0.253e3.074)
(0.144e1.627)
(1.026e11.454)

0.8
0.8
0.2
0.04*

11.9 ± 2.3
9.9 (4.7e15.8)
13 (65.0%)
254.0 (202.0e335.3)
1.1 (1.0e1.2)
154.0 (104.0e306.0)
628.5 (494.0e928.3)

11.7 ± 2.7
7.0 (4.2e12.0)
45 (62.5%)
272.0 (173.3e363.0)
1.1 (1.1e1.2)
135.5 (56.3e361.0)
534.0 (219.5e749.8)

0.6
0.3
0.8
0.9
0.2
0.3
0.04*

1.043
0.997
1.114
1.000
0.018
1.000
1.002

(0.860e1.266)
(0.978e1.017)
(0.396e3.138)
(0.997e1.003)
(0.001e1.679)
(1.000e1.001)
(1.000e1.003)

0.6
0.7
0.8
0.8
0.08
0.3
0.02*

2.3 (0.5e14.5)
3.5 (2.6e3.8)
9.1 (7.0e10.2)
158.5 (105.3e204.5)
86.0 (56.6e100.3)
5.3 (4.4e13.0)
8.0 (7.7e10.6)
49.0 (33.3e87.0)

1.0 (0.4e3.8)
0.04 (0.01e0.2)
1.0 (0.6e1.3)
24.0 (3.5e36.0)
79.0 (61.8e94.0)
6.0 (4.7e9.8)
10.4 (5.0e16.0)
44.5 (28.3e80.3)

0.1
0.001**
0.001**
0.001**
0.7
0.7
0.6
0.8

1.032 (0.990e1.076)
1.016 (0.971e1.067)
1.021 (1.012e1.028)
1.025 (1.015e1.035)
0.998 (0.989e1.007)
0.972 (0.918e1.029)
0.962 (0.889e1.041)
1 (0.991e1.009)

0.1
0.01*
0.001**
0.001**
0.6
0.3
0.3
0.9

29.5 (26.3e55.0)

33.5 (20.0e71.0)

0.9

0.993 (0.973e1.014)

0.5

18.0 (8.6e23.8)
140.4 ± 2.9

9.3 (7.8e14.0)
140.4 ± 2.7

0.01*
0.9

1.036 (0.999e1.074)
0.997 (0.831e1.195)

0.05*
0.9

0 (0.0%)

2 (2.8%)

0.4

0.792 (0.118e1.027)

0.7

2 (10.0%)
3 (15.0%)
19 (95.0%)
2 (10.0%)

3 (4.2%)
7 (9.7%)
39 (54.2%)
3 (4.2%)

0.3
0.5
0.001**
0.3

2.556 (0.397e16.463)
1.639 (0.383e7.014)
16.077 (2.042e126.597)
2.556 (0.397e16.463)

0.3
0.5
0.01*
0.3

(35.0%)
(20.0%)
(0.0%)
(5.0%)
(0.0%)

Age, HB, and Na are represented as Mean ± SD; the data were analyzed by student t test. While Sex, Nationality, Delay, Smoker,
Obesity, HTN, CKD, DM, CVA, IHD, Lung dis., Leucopenia, SOB, Fever, Cough, Pneumonia, ARDS, Septic shock, RF, ICU admission
and Death Rate are represented as frequency and percent; the data were analyzed by X2 test. But Delay, WBC, PLT, INR, CK, LDH,
CKMB, cTn I, D.dimer, CRP, Cr, Urea, B. sugar, AST, ALT, T. bilirubin and Na are represented as Median with Interquartile range
(25%e75%), the data were analyzed by Mann-whitney U test.
OR; Odd Ratio, C$I; Conﬁdence Interval, p-value calculated depend on logistic regression analysis.
Septic shock is deﬁned by persisting hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or higher
and a serum lactate level greater than 2 mmol/L (18 mg/dL) despite adequate volume resuscitation.
*p. value < 0.05 is signiﬁcant, **p. value < 0.01 is highly signiﬁcant.

Fig. 1. Different CT ﬁndings in COVID-19 patients with acute pulmonary embolism.

(19.04%) patients underwent chest CT scans. Patients were categorized according to their chest CT
scan results into two groups: one with APE and one
without PE (Non-PE).
The demographic characteristics of both groups are
presented in Table 1. In both the APE and non-PE
groups, men represented the majority of patients, at
17 (85.0%) and 55 (76.4%), respectively. The mean
ages of patients underwent chest CT scans was
48.9 ± 16.7 in the APE group and 47.7 ± 14.8 years in
non-PE group. Most patients in both groups were
non-Saudi nationals, including 17 (85.0%) in the APE
group and 55 (76.4%) in non-PE group. The diagnosis
of PE, based on results of chest CT, occurred later in
the APE group than in the non-APE group, by an
average of 4 days (range 1.0e12.8 days). However, this
difference was not signiﬁcant compared with the nonPE group (average 1 day, range 1.0e12.0 days).
Diabetes, identiﬁed in 35.0% (7/20) patients, was
the most prevalent comorbidity identiﬁed in the
APE group, followed by hypertension, which was
identiﬁed in 20.0% (4/20) patients. For most patients
with APE, risk factors for thromboembolism were
established, but these did not differ signiﬁcantly
from those in patients without PE, except for a history of chronic kidney disease, which was absent
from the APE group.
Fever and shortness of breath were the most
commonly identiﬁed clinical presentations for both
groups, with no signiﬁcant difference in incidence.
However, pneumonia incidence was signiﬁcantly
higher among the APE group, identiﬁed in 30.0% (6/
20) of patients in the APE group compared with only
11.1% (8/20) patients in the non-PE group (P ¼ 0.03).
Patients with APE were more frequently admitted to
the ICU than those without PE [19 (95.0%) vs 39
(54.2%) patients, P ¼ 0.001]. Moreover, the in-hospital fatality rate was 2 (10.0%) in the APE group
versus 3 (4.2%) in the non-PE group.
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The laboratory tests for patients with APE showed
signiﬁcantly elevated levels compared with those for
patients in the non-PE group. The mean D-dimer
[9.1 (range: 7.0e10.2) vs. 1.0 (range: 0.6e1.3); OR:
1.021; 95% CI: 1.012e1.028; P ¼ 0.001], LDH [628.5
(range: 494.0e928.3) vs. 534.0 (range: 219.5e749.8);
OR: 1.002; 95% CI: 1.000e1.003; P ¼ 0.02], CRP [158.5
(range: 105.3e204.5) vs. 24.0 (range: 3.5e36.0); OR:
1.025; 95% CI: 1.015e1.035; P ¼ 0.001], cardiac
troponin [3.5 (range: 2.6e3.8) vs. 0.04 (range:
0.01e0.2); OR: 1.016; 95% CI: 0.971e1.067; P ¼ 0.01],
and total bilirubin [18.0 (range: 8.6e23.8) vs. 9.3
(range: 7.8e14.0); OR: 1.036; 95% CI: 0.999e1.074;
P ¼ 0.05] levels were all signiﬁcantly elevated in the
APE group vs. the non-PE group.
According to Saudi MOH Protocol for Patients of
Conﬁrmed with COVID-19, which KSMC follows,
thromboprophylaxis with low molecular weight
heparin (LMWH) should be considered in all patients (including non-critically ill) who require hospital admission for COVID-19 infection, in the
absence of any contraindications (active bleeding
and platelet count less than 25 x 109/L; monitoring is
advised in severe renal impairment; abnormal PT or
APTT is not a contraindication). Dose of LMWH
depend on level of D-dimer; is it less or more than 1
mcg/mL.The decision to conduct chest CT scan was
based on acute hemodynamic or respiratory status
deterioration and suspicion of PE. The CT ﬁndings
for patients with APE displayed sub-segmental PE
in 7 patients (35.0%), segmental PE in 4 patients
(20.0%), both segmental and sub-segmental PE in 4
patients (20.0%), multi-segmented PE in 1 patient
(5.0%), lobar PE in 1 patient (5.0%), and massive PE
in 3 patients (15.0%, Fig. 1).

4. Discussion
The incidence of APE among our COVID-19 patients was 22% (95% CI: 19%e39%), based on chest
CT results. The incidence of APE among COVID-19
patients based on pulmonary CT angiography was
reported between 23% and 30% in recent studies
[13,14], which is nearly similar to our results (22%).
This high prevalence of PE among COVID-19-positive patients supports an increasing awareness of
the relationship between COVID-19 and hypercoagulable conditions [15].
Our patients presented with classic COVID-19
manifestations, including fever, cough, and shortness of breath. Similarly, several publications have
reported the diagnosis of PE among patients with
COVID-19 who presented with common COVID-19
manifestations [16,17]. Unlike Grillet et al., who reported the delayed diagnosis of APE among
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COVID-19 patients, after a mean of 12 days from
symptom onset [13], our patients were diagnosed
with APE nearly four days earlier.
Signiﬁcant differences between the CRP and Ddimer levels between the APE and non-PE groups
have been observed, which may suggest that
COVID-19-positive patients with higher inﬂammation rates are more likely to experience thrombotic
events. Elevated levels of D-dimer in patients with
COVID-19-associated pneumonia have also been
reported by several studies [18,19]. Several studies
have shown a strong association between elevated
D-dimer levels and poor COVID-19 prognosis
[20e23]. However, a positive D-dimer test is not an
absolute diagnostic criterion for PE because other
clinical conditions (for example, cancer, infection,
pregnancy, or postoperative status) have also been
associated with high D-dimer levels [24,25].
The laboratory ﬁndings for the PE group in our
study also showed signiﬁcantly higher levels of
Troponin, LDH, and total bilirubin compared with
the non-PE group. Similarly, Guo et al. reported that
the levels of plasma troponin had a positive, direct,
linear correlation with the levels of high-sensitivity
plasma CRP, which indicated that myocardial injury
might be closely linked to inﬂammatory pathogenesis during COVID-19 progression [26]. In addition,
elevated troponin T concentrations in patients with
PE have been associated with higher in-hospital
mortality rates [27]. Moreover, increased CRP levels
were associated with adverse aspects of COVID-19,
such as ARDS, and increased LDH levels have also
have been associated with an increased risk of
ARDS [28], higher ICU admission rates [29], and
increased mortality [20,25].
A previous study, which described a series of 8
patients complicated with PE following COVID-19
infection, also reported high levels of D-dimer, total
bilirubin, liver enzymes, and LDH [30].
Our APE patients showed a high frequency
(95.0%) of ICU admission, which agrees with the
study by Klok et al., who reported a high incidence
of PE with thrombotic complications among positive
COVID-19 patients admitted to the ICU (65/75; 87%)
[31]. In addition, Grillet et al. reported that COVID19 Patients with pulmonary embolus were more
likely than those without to be admitted to the
critical care unit, (17/23; 74%) vs (22/77; 29%) patients, respectively; P, 0.001 [18].
Our study identiﬁed that speciﬁc clinical data
might serve as potential predictors for PE among
COVID-19-positive patients. Multivariate analysis
revealed that higher levels of D-dimer, CRP, LDH,
cardiac troponin, and total bilirubin levels were
crucial predictors of APE complicating COVID-19

infection. Our observations meet with Helms J et al.
who stated that Despite anticoagulation, a high
number of COVID-19 patients experienced lifethreatening thrombotic complications, the most
common of which were pulmonary embolisms
(16.7%), during their ICU admission [32].
Our study reafﬁrmed the link between increased
D-dimer levels and the development of ARDS in
COVID-19 patients, which is considered to be a risk
factor for micro-PE. Moreover, previous studies
[20,33,34] have reported that D-dimer levels tend to
be a critical parameter for the assessment of
COVID-19 severity. D-dimer also adds value to the
prediction of APE risk among COVID-19-positive
patients. Our study showed that APE risk factors in
COVID-19 patients do not include the typical
thrombo-embolic risk factors; instead, independent
clinical and laboratory predictors can be used to
assess risk, which reﬂects the signiﬁcant contribution of inﬂammation.
A recent study reported higher signiﬁcant mortality in COVID-19 patients with PE as compared
with non-PE patients (16/32; 50%) vs (52/192; 27%),
respectively; P, 0.010 [35]. In our study, the fatality
rate was insigniﬁcantly higher in APE group than in
those in non-APE group.This insigniﬁcance may be
related to quite small sample size.
PE, in our study, was most frequently observed in
the subsegmental and segmental pulmonary arteries, or both (75%), whereas the remaining cases
were distributed between multisegmented, lobar,
and massive PE. This ﬁnding agrees with previous
studies that reported that PE in COVID-19 is more
typically identiﬁed in the peripheral parts of the
lungs [34e39], which is compatible with the observation of microthrombi formation [38,39]. These
sites also tend to conform to the most typical
COVID-19 opacity distribution [38]; however, other
studies have also reported massive PE among
COVID-19 patients [27,40].
Our research limitations include the retrospective
study design and the constraint to a single health
system. However, our results may help to alert the
medical community regarding the increased risk of
PE among COVID-19 patients and provided evidence of some potentially predictive factors that can
be used to identify COVID-19 patients at high risk
for PE.
We conclude that due to symptom overlap, the
differentiation between COVID-19 and PE presents
a diagnostic challenge for doctors in emergency
care. More than one-ﬁfth of patients hospitalized for
COVID-19 pneumonia presented with APE on chest
CT. The early diagnosis and timely treatment of
COVID-19 patients complicated with APE are

crucial for reducing mortality. These results suggest
that chest CT evaluations should be more widely
used in patients with COVID-19 pneumonia, especially those with marked D-dimer elevation.

[8]
[9]
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